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Background: Due to excessive antibiotic use, drug-resistant Mycobacterium tuberculosis has become a serious
public health threat and a major obstacle to disease control in many countries. To better understand the evolution
of drug-resistant M. tuberculosis strains, we performed whole genome sequencing for 7M. tuberculosis clinical
isolates with different antibiotic resistance profiles and conducted comparative genomic analysis of gene variations
among them.
Results: We observed that all 7M. tuberculosis clinical isolates with different levels of drug resistance harbored similar
numbers of SNPs, ranging from 1409–1464. The numbers of insertion/deletions (Indels) identified in the 7 isolates were
also similar, ranging from 56 to 101. A total of 39 types of mutations were identified in drug resistance-associated loci,
including 14 previously reported ones and 25 newly identified ones. Sixteen of the identified large Indels spanned
PE-PPE-PGRS genes, which represents a major source of antigenic variability. Aside from SNPs and Indels, a CRISPR
locus with varied spacers was observed in all 7 clinical isolates, suggesting that they might play an important role in
plasticity of the M. tuberculosis genome. The nucleotide diversity (Л value) and selection intensity (dN/dS value) of the
whole genome sequences of the 7 isolates were similar. The dN/dS values were less than 1 for all 7 isolates (range
from 0.608885 to 0.637365), supporting the notion that M. tuberculosis genomes undergo purifying selection. The Л
values and dN/dS values were comparable between drug-susceptible and drug-resistant strains.
Conclusions: In this study, we show that clinical M. tuberculosis isolates exhibit distinct variations in terms of the
distribution of SNP, Indels, CRISPR-cas locus, as well as the nucleotide diversity and selection intensity, but there are
no generalizable differences between drug-susceptible and drug-resistant isolates on the genomic scale. Our study
provides evidence strengthening the notion that the evolution of drug resistance among clinical M. tuberculosis isolates
is clearly a complex and diversified process.
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EvolutionBackground
The emergence and transmission of drug-resistant M.
tuberculosis strains, especially Multidrug-resistant (MDR)
and extensively drug-resistant (XDR) strains pose signifi-
cant clinical, economic, as well as societal challenges. Ac-
cording to WHO report, there were an estimated 8.6
million incident cases of TB worldwide in 2012. Most of
the estimated number of cases in 2012 occurred in Asia
(58%) and the African Region (27%). The five countries* Correspondence: liucuihua@im.ac.cn; zhubaoli@im.ac.cn
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reproduction in any medium, provided the orwith the largest number of incident cases include: India
(2.0–2.4 million, in 2012), China (0.9–1.1 million, in
2012), South Africa (0.4–0.6 million, in 2012), Indonesia
(0.4–0.5 million, in 2012) and Pakistan (0.3–0.5 million, in
2012). India and China alone accounted for 26% and 12%
of global cases, respectively. In addition, the global esti-
mate of the burden of MDR-TB was 300, 000 cases among
notified TB patients in 2012. India and China were the
two countries estimated to have the largest numbers of
MDR-TB patients (both over 50,000) [1]. The latest na-
tionwide baseline survey for TB drug resistance carried
out in China for the 2007 and 2008 reported that 8.32%
of pulmonary TB patients in China suffered from MDR-
TB and 0.68% from XDR-TB. In 2007, there were anThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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incident cases of XDR-TB [2]. Furthermore, most cases of
MDR- and XDR-TB were shown to be the result of pri-
mary transmission, suggesting that many of the new TB
cases suffer from the most intractable types of highly
drug-resistant M. tuberculosis strains [2,3]. Antibiotic sus-
ceptibility profiles and the corresponding resistance deter-
minants of M. tuberculosis have been extensively reported.
However, the genome variations and evolution of drug re-
sistance in M. tuberculosis are still not well explained. De-
termining the genome components and variations within
natural populations of M. tuberculosis isolates with differ-
ent antibiotic susceptibility profiles may provide a novel
perspective on the evolution of drug resistance in M. tu-
berculosis and enable us to better understand and control
drug-resistant TB.
The Mycobacterium tuberculosis complex (MTBC) lin-
eages were considered to be monomorphic, but more
and more studies have confirmed the extensive genetic
diversity and genome plasticity of the mycobacterial
genome through molecular typing techniques such as
IS6110-RFLP, spoligotyping, and MIRU-VNTR [4-6].
With the advent of high throughput Next Generation
Sequencing technologies (NGS), multiple genome se-
quences from different strains of a single species can
provide comprehensive information for exploring the
relationship between genotypes and phenotypes with
unprecedented resolution. In this study, we used the
Illumina GAIIx sequencing platform to generate a high-
quality and annotated draft genome for 7M. tuberculosis
clinical isolates with different antibiotic resistance phe-
notypes in order to better understand the evolution of
drug resistance in M. tuberculosis isolates in a clinical
context. Comparative genomic analyses of these 7 strainsTable 1 Epidemiologic and clinical data of clinical M. tubercul
Isolates Type Drug resistance profilesa Age,
years
Gend
Mtb562 Susceptible None 22 Male
Mtb526 MDR INH, RMP, STR 39 Male
Mtb194 Pre-XDR INH, RMP, STR, EMB, OFX, LVX 21 Fema
Mtb293 Pre-XDR INH, RMP, OFX, LVX, PAS, ETH 35 Fema
Mtb940 Pre-XDR INH, RMP, STR, EMB, PAS, OFX, LVX,
ETH
63 Male
Mtb984 XDR INH, RMP, STR, EMB, OFX, LVX, KAN 72 Male
Mtb43 XDR INH, RMP, STR, EMB, PZA, OFX, LVX,
KAN, CAP, AMK, PAS, ETH
47 Male
n.a. = not available.
aINH, isoniazid; RMP, rifampicin; STR, streptomycin; EMB, ethambutol; PZA, pyrazina
AMK, amikacin; PAS, para-amino salicylic acid; ETH, ethionamide.as well as 7 other previously published M. tuberculosis
genomes have revealed some genomic variations which
might underlie diverse phenotypes among those strains,
but no generalizable differences were identified between
drug-susceptible and drug-resistant isolates on the gen-
omic scale. Our study adds some new knowledge on
genomic variability and evolution of drug-resistant M.
tuberculosis.
Results
Whole genome sequencing statistics
The detailed epidemiologic and clinical data of the
selected M. tuberculosis isolates were summarized in
Table 1. The basic whole genome sequencing statistics
are shown in Additional file 1: Table S1. The coverage
ranged between 200× and 560×, and the completion was
97.43-97.82%. By comparing the sequenced M. tubercu-
losis clinical isolates to H37Rv, we observed that all 7
isolates with different levels and profiles of drug resist-
ance harbored similar numbers of SNPs, ranging from
1409–1464. The numbers of insertion/deletions (Indels)
identified in the 7 isolates were also similar, ranging
from 56 to 101.
SNP clustering and distribution in the M. tuberculosis
genomes
Further comparative genomic analysis identified a total
of 1871 non repetitive SNPs, among which a common
pool of 1102 SNPs were shared by the 7 isolates. More
detailed information on total SNPs as well as SNPs
in each isolate relative to H37Rv are summarized in
Additional file 2: Table S2. To identify regions of SNP
clustering, SNP density was estimated throughout the











Liaoning 2010 New Cure 223224163533-
454334682431
Shanxi 2011 Retreated Cure 233224163533-
454344672432
le Beijing 2010 New Cure 213224163433-
243344572422
le Heilongjiang 2009 n.a. n.a. 233324163523-
454344682432
Hebei 2010 New Cure 233324143533-
254344672432
Anhui 2011 Retreated Cure 233424173534-
254344482432
Henan 2009 Retreated Died 232224153433-
454344582432
mide; OFX, ofloxacin; LVX, levofloxacin; KAN, kanamycin; CAP, capreomycin;
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SNPs, with 25 regions having statistically significant
clusters (red bars in Figure 1). The detailed information
on the 25 regions with significantly high SNP density is
shown in Additional file 2: Table S2. We further ana-
lyzed the distribution of SNPs according to the different
classes of the Clusters of Orthologous Groups (COG)
[7-9]. We found that SNPs were significantly under-Figure 1 SNP density map constructed using Circos. Note: Green bars
means the regions with significantly high SNP density.represented in genes belonging to secondary metabolites
biosynthesis, transport, and catabolism (class Q), while
genes whose functions were unknown (class S) were sig-
nificantly enriched in SNPs (p < 0.01) (Additional file 3:
Figure S1). SNPs were also slightly over-represented in
genes belonging to several other classes such as class
M (Cell wall/membrane/envelope biogenesis), class R
(General function), class V (Defense mechanisms), classmeans the density of SNPs in non-overlapping 5-kb regions; Red bars
Liu et al. BMC Genomics 2014, 15:469 Page 4 of 13
http://www.biomedcentral.com/1471-2164/15/469J (Translation, ribosomal structure and biogenesis), class
K (Transcription), class T (Signal transduction mecha-
nisms), and class N (Cell motility).Genomic insertions and deletions
We further analyzed large insertions and deletions (des-
ignated as those insertions or deletions are of 20 base
pair long or above) in clinical M. tuberculosis relative to
M. tuberculosis H37Rv. In total, 1 non strain-specific
and 29 strain-specific large insertions as well as 2 non
strain-specific and 61 strain-specific large deletions were
identified. Sixteen of those Indels spanned PE-PPE-
PGRS genes, which have been considered a major source
of antigenic variability [10]. Many Indels were identified
both in drug-susceptible and drug-resistant strains.CRISPR distribution in the M. tuberculosis genomes
CRISPRfinder was used to identify putative CRISPR loci
in the genomes of the 7M. tuberculosis isolates. In con-
trast to the M. tuberculosis lab strain H37Rv, which was
predicted to have two CRISPR loci, all the 7 clinical M.
tuberculosis isolates sequenced in this study as well as
two other previously sequenced clinical M. tuberculosis
isolates (including CCDC5079 and CCDC5180) were
predicted to have only one of the two CRISPR loci.
While the spacers in the CRISPR were identical among 5
clinical isolates including CCDC5079, CCDC5180 and
three of our clinical isolates (Mtb562, Mtb 526 and
Mtb43), other isolates had high variability in the spacers
(Additional file 4: Figure S2). No correlation betweenTable 2 SNPs and Indels identified in antibiotic resistance-ass














Mtb562 None None T70(del),E321e,f,I322Vf,g None None
Mtb526 None None T70(del),E321e,f,I322Vf,g S315Td,g,R463Lg D200
Mtb194 None None T70(del),E321e,f,I322Vf,g R463Lg D200
Mtb293 None None T70(del),E321e,f,I322Vf,g C171Gf,g,R463Lg D200
Mtb940 None None T70(del),E321e,f,I322Vf,g R463Lg D200
Mtb984 None G3 e,f T70(del),E321e,f,I322Vf,g S315Td,g,R463Lg D200
Mtb43 T-8Cd G3 e,f T70(del),E321e,f,I322Vf,g S315Td,g,R463Lg D200
a“R”, resistance of isolates to the corresponding anti-TB drug; “S”, sensitivity of isola
rifampicin; STR, streptomycin; EMB, ethambutol; PZA, pyrazinamide; OFX, ofloxacin;
ETH, ethionamide.
bintergenic regions.
cnucleotide mutational position is relative to Mycobacterium tuberculosis H37Rv rpoB
ddrug resistance-asssociated mutations with high confidence.
esynonymous.
fnewly identified mutations.
gnon-synonymous.antibiotic resistance and the presence of CRISPR-cas
locus was observed.Gene mutations associated with drug resistance in
M. tuberculosis
The detailed information on mutations identified in drug
resistance-associated loci of the 7 Chinese clinical iso-
lates is summarized in Table 2 and 3. A total of 39
types of mutations were identified in drug resistance-
associated loci, including 14 previously reported ones
and 25 newly identified ones. The levels of correlation
between phenotypic drug resistance and drug resistance-
associated mutations varied greatly for different drugs,
ranging from 0% (for para-aminosalicylic acid and
ethionamide) to 100% (isoniazid). We also identified
20 known or putative drug efflux pumps with non-
synonymous SNPs in MDR, pre-XDR and XDR M. tu-
berculosis isolates but not in H37Rv strain (Additional
file 5: Table S3). We further over expressed the mutated
drug efflux pump genes in the drug-susceptible refer-
ence H37Rv strain and determined MICs of those re-
combinant strains. No increased drug resistance was
observed for all examined strains over expressing mu-
tated drug efflux pump genes. We also performed
genetic studies by creating point mutations in the sus-
ceptible reference strain H37Rv using the pJV53K sys-
tem for some other potential drug resistance-associated
mutations identified in this study [11], but also could
not confirm their function in causing drug resistance













None None A1075e,f None
e,f,D229Gg S40Nf,g None L511Pd,g,
A1075e,f
K43Rd,g,K121e,f
e,f,D229Gg None None A1075e,f K121e,f
e,f,D229Gg None None A1075e,f K121e,
e,f,D229Gg None None A1075e,f K121e,f
e,f,D229Gg None F128e,f L511Pd,g,S512Gg,
D516Gg,A1075e,f
K43Rd,g,K121e,f
e,f,D229Gg None None S531Ld,g K43Rd,g,K121e,f
tes to the corresponding anti-TB drug; “del”, deletion; INH, isoniazid; RMP,
LVX, levofloxacin; KAN, kanamycin; CAP, capreomycin; AMK, amikacin;
, and amino acid position is relative to Escherichia coli numbering.
Table 3 SNPs and identified in antibiotic resistance-associated regions in M. tuberculosis isolates



















Mtb562 S100Fg R927e None None None S95Tg None None Q360Hg
Mtb526 E92Dg,S100Fg,A205e V885Mf,g,R927e C76e None None E21Qg,S95Tg,G668Df,g None L11e Q360Hg
Mtb194 E92Dg,S100Fg,A205e V885Mf,g,R927e C76e None None E21Qg,S95Tg,G668Df,g None L11e Q360Hg
Mtb293 E92Dg,S100Fg,A205e V885Mf,g,R927e C76e None None E21Qg,S95Tg,G668Df,g None L11e Q360Hg
Mtb940 E92Dg,S100Fg,A205e V885Mf,g,R927e C76e None None E21Qg,S95Tg,G668Df,g None L11e Q360Hg
Mtb984 E92Dg,S100Fg,A205e V885Mf,g,R927e G5Sf,g,C76e G406Sd,g F94Sf,g E21Qg,D94Gd,g,S95Tg, G668Df,g None L11e Q360Hg
Mtb43 E92Dg,S100Fg,A205e V885Mf,g C76e M306Vd,g T76Ig E21Qg,D94Gd,g,S95Tg,G668Df,g G1332A,A1401G L11e P164Lf,g,Q360Hg
a“R”, resistance of isolates to the corresponding anti-TB drug; “S”, sensitivity of isolates to the corresponding anti-TB drug; “del”, deletion; INH, isoniazid; RMP,
rifampicin; STR, streptomycin; EMB, ethambutol; PZA, pyrazinamide; OFX, ofloxacin; LVX, levofloxacin; KAN, kanamycin; CAP, capreomycin; AMK, amikacin; ETH, ethionamide.
bintergenic regions.
cnucleotide mutational position is relative to Mycobacterium tuberculosis H37Rv rpoB, and amino acid position is relative to Escherichia coli numbering.






















Figure 2 Phylogenetic relationships of M. tuberculosis isolates based on SNPs from whole genome sequences. The trees were constructed
by the neighbor-joining method (A) or maximum-likelihood method (B). Only bootstrap values >50% are shown (n = 1000 replicates).
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tuberculosis genomes
We used the whole genome sequences of the M. tuber-
culosis isolates for genetic diversity and selection inten-
sity analysis and the data were shown in Additional file
6: Table S4. The nucleotide diversity (Л value) for the
whole genome sequences of the 7 newly sequenced
clinical isolates were similar, ranging from 0.00033 to
0.00036. There was no significant differences in Л values
between drug-susceptible isolates and drug-resistant iso-
lates (0.00024 versus 0.00021), while the Л value was
significantly higher among clinical isolates (0.00033) as
compared with lab strains (0.00004). The dN/dS values
for the whole genome sequences were similar among
isolates with different drug resistance profiles, ranging
among 0.608885 to 0.637365. There was no significant
differences in dN/dS values between drug-susceptible iso-
lates and drug-resistant isolates (0.66891 versus 0.687259),
while the dN/dS value was significantly lower among clin-
ical isolates (0.66018) as compared with lab strains
(0.765664). We observed significant differences in Л
values between our 7 clinical isolates and 5 previously de-
scribed clinical isolates (0.00008 versus 0.00057). But when
we analyzed our 7 isolates together with the two Beijing
lineage strains (CCDC5079 and CCDC5080) from the 5
previously described clinical isolates, the Л value increased
from 0.00008 to 0.00028.
Phylogenetic analysis of M. tuberculosis isolates
Two phylogenetic trees including a neighbor-joining (NJ)
tree and a maximum-likelihood (ML) tree were created
based on SNPs from whole genome sequences of the 7clinical M. tuberculosis isolates and other 7 completely
sequenced M. tuberculosis strains. The phylogenetic
relationships among different clinical isolates were similar
in two phylogenetic trees (Figure 2). The 7 newly se-
quenced Chinese clinical isolates as well as the two previ-
ously sequenced Beijing lineage strains CCDC5079 and
CCDC5180 formed a single clade.
Discussion
To determine the genome components and variations
within natural populations of M. tuberculosis isolates
and to better understand the evolution of drug resist-
ance among those isolates, we explored the feasibility of
using deep genome sequencing to characterize variations
in clinical M. tuberculosis isolates with different drug
susceptibility profiles. Our results suggest that the level
of genetic diversity is independent of the drug resistance
phenotype, since the isolates with different drug resist-
ance profiles harbored similar numbers of SNPs, nucleo-
tide diversity (Л values), and selection intensity (dN/dS
values). The relatively high number of SNPs we identi-
fied in all isolates could be partially caused by natural
variation, as we included all genes from 7 strains isolated
from patients diversely located. Selective diversification
of M. tuberculosis isolates might also explain an associ-
ation between host response and strain genetic back-
ground as previously reported [12,13]. Several lines of
evidence in this study support a significant role of nat-
ural selection in shaping M. tuberculosis genomes. First,
the SNP distribution in genomes is not random, suggest-
ing that diversifying selection is at work notably in cer-
tain genes such as those that play a role in cell wall/
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function (class R), which tend to accumulate an excess
of SNPs [7,12,14,15]. Second, in the SNP density map,
many genes located in the regions with significantly high
SNP density are involved in host–pathogen interactions
and may contribute to strain-specific virulence attri-
butes. For example, one region corresponds to a previ-
ously reported virulence operon including the genes
Rv0986–Rv0988 that are present in one of horizontal
genetic transfer (HGT) regions [7,16,17]. Another region
with high density of SNPs was found in the ESX-1 locus
(RD1 region), which includes a type VII secretion system
[18]. But in the absence of the information about strain-
specific differences in virulence, the high number of
SNPs could also be the result of lateral gene transfer.
Third, the dN/dS values were less than 1 for the genomes
of all 7 isolates analyzed, consistent with genome-wide
purifying selection. We have previously shown that the
dN/dS values for coding regions of drug resistance-
associated genes in MDR and XDR isolates were higher
than 1, suggesting that exposure to drugs is among the
major forces driving the high dN/dS ratios in those drug
resistance-associated genes [19]. But as suggested in this
study, on the genome-wide scale, the clinical M. tubercu-
losis strains with different drug resistance profiles undergo
similar levels of purifying selection. Consistently, results
from a recent study suggest that the dominant effect of se-
lection on natural M. tuberculosis population is removal of
novel variants, with exceptions in certain group of genes
such as those involved in defense [20].
Indels have a wide range of effects as a very important
cause of phenotypic variability. The acquisition and loss
of certain genes could provide pathogens with some ad-
vantages during infection and transmission. Thus, the
Indel loci identified in this study are candidates for drug
resistance or virulence-associated factors that may repre-
sent evolutionary signatures during the co-evolution of
humans and pathogens. For example, the deletion of a
polyketide synthase gene (pks5) with high homology to
mycocerosic acid synthase is particularly intriguing be-
cause the product of this gene may be involved in the
production of multimethylated branched lipids [21]. In
addition, the pks5 mutant strain of M. tuberculosis
H37Rv was shown to display severe growth defects in
mice [22]. It is also worth noting that sixteen of those
Indels spanned PE-PPE-PGRS genes, which have been
considered a major source of antigenic variability [10].
In addition, two of those unique proteins code for
putative membrane proteins (including MmpL1 and
MmpL4) and may directly alter the interactions between
pathogens and their hosts [23]. Since we identified
many Indels including some of those above-mentioned
virulence-associated genes within both drug-susceptible
and drug-resistant strains, our results suggest that drugresistance in M. tuberculosis is not necessarily an indica-
tion of increased virulence. Our findings are consistent
with the notion that the virulence of individual clinical
M. tuberculosis isolate is dependent on multiple factors
including strain genetic background and host immune
responses [24].
A highly significant inverse correlation between the
presence of CRISPR-cas locus and acquired antibiotic re-
sistance was observed in E. faecalis, suggesting that anti-
biotic use inadvertently selects for enterococcal strains
with compromised genome defense [25]. But in this
study, no functional genes were identified in CRISPR
locus and no correlation between antibiotic resistance
and the presence of CRISPR-cas locus was observed in
clinical M. tuberculosis isolates.
Using our previously established method of automatic
TBDReaMDB-coupled analysis for drug resistance-associated
mutations in M. tuberculosis isolates [19], we detected 25
types of unreported mutations, as well as 20 known or pu-
tative drug efflux pumps with non-sense SNPs in MDR,
pre-XDR and XDR M. tuberculosis isolates, but we could
not establish the association between over expression of
those mutated drug efflux pumps with increased drug re-
sistance in M. tuberculosis. It was reported previously that
mutations or overexpression of Rv0194 and Rv2686c are
associated with increased resistance to multiple drugs in
M. tuberculosis [26,27]. But according to another recent
study which aimed to compare the differences of the ex-
pression of 15 putative multidrug efflux pump genes in
clinically isolated drug sensitive and MDR M. tuberculosis
isolates, all the tested putative multidrug efflux pump
genes in the drug-sensitive and MDR M. tuberculosis iso-
lates have similar rates of expression [28]. Thus, the exist-
ence of mutations and over expression of the efflux pump
genes might not be necessarily associated with increased
drug resistance.
By closely examining the correlation of the phenotypic
drug susceptibility profiles of the strains with mutations
identified in their drug resistance-associated genes, we
identified a few potential new genetic determinants
of drug resistance. For example, while 5 (Mtb194,
Mtb293, Mtb940, Mtb984, Mtb43) of the 7 strains exhib-
ited phenotypic resistance to ofloxacin and levofloxacin,
only 2 of them (Mtb984 and Mtb43) had gyrA D94G
mutation known to confer resistance to fluoroquino-
lones. The other 3 had the same gyrA E21Q, G668D,
and S95T mutations seen in fluoroquinolone susceptible
strain Mtb526, indicating that these mutations are
not the source of fluoroquinolone resistance. Similarly,
among the 6 strains showing phenotypic resistance to ri-
fampicin, 3 (Mtb194, Mtb293, Mtb940) only had the
rpoB A1075 mutation, which was also present in the
susceptible strain, suggesting the presence of other un-
known mechanisms for rifampicin resistance in them.
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other drug resistance-associated genes such as gyrB,
gidB and eis in those strains [29], we then performed
genetic studies for those newly identified potential
drug resistance-associated mutations, but failed to con-
firm their function in causing drug resistance either
(data not shown). Thus, our observations demonstrated
that though certain drug resistance-associated mutations
such as rpoB S531L, katG S315T, gyrA D94G, embB
M306V, rpsL K43R, and rrs A1401G could serve as use-
ful markers for rapid detection of resistance in the clin-
ical M. tuberculosis isolates, the accuracy and sensitivity
of genetic-based drug resistance assays still need to be
increased by further elucidation of unknown mecha-
nisms of drug resistance, especially for second-line drugs
[29-31]. It should also be pointed out that confirming
drug resistance-associated mutations by genetic study
could only examine the function of individual gene
mutation without taking into consideration the whole
genetic background of the strain, while based on the
whole genome sequencing studies by us and a few
others, there might be no common causes of drug resist-
ance to multiple drugs. Rather, the MDR and XDR phe-
notypes could result from a combination of mutations in
the genomes [15,32,33].
The phylogenetic relationships among different clinical
isolates were similar in two phylogenetic trees based on
whole genome SNPs. The whole genome sequencing has
been proposed as a sort of “gold standard” for strain typ-
ing in M. tuberculosis since it clarifies previous strain
typing approaches used for phylogenetic and epidemio-
logic studies and provides more detailed genomic vari-
ation information. The observation that MDR, pre-XDR,
and XDR isolates were located sporadically on different
branches in phylogenetic trees based on SNPs from
whole genome sequences of the 14M. tuberculosis iso-
lates further confirms our previous observation that they
have evolved and acquired mutations independently on
multiple occasions. The observation that isolates from
China were phylogenetically distant from the isolates
from other regions such as the KZN strain from South
Africa in the phylogenetic trees also confirmed our
previous observation that drug-resistant M. tuberculosis
strains from different geographic regions have distinct
evolutionary pathways [19]. The close phylogenetic re-
latedness among the 7 clinical M. tuberculosis isolates
could also be best supported by the analysis of specific
SNPs in drug resistance-associated genes. The presence
of identical uncommon mutations in many of those
genes among the 7 strains (e.g. I322V in Rv1592c, R463L
in katG, A1075 in rpoB, G668D in gyrA etc.) is indicative
of a single cluster of strains circulating in the popula-
tion. The finding of high levels of clustering and min-
imal strain diversity among MDR/XDR M. tuberculosisstrains within a population has been described previ-
ously [34].
This study has several limitations. Firstly, since the 7
clinical M. tuberculosis isolates included in the analysis
all belonged to the Beijing lineage, thus it is possible that
similarities and differences between different strain
groups may be explained by phylogenetic lineages, rather
than phenotypic differences. By comparing our 7 clinical
isolates with 5 previously described clinical isolates from
diverse lineages and countries of origin, we did observe
significantly higher Л value for those 5 previously de-
scribed clinical isolates. However, when we analyzed our
7 Beijing lineage isolates together with two previously
described Beijing lineage isolates (CCDC5180: resistant
to four first-line drugs; CCDC5079: susceptible strain),
the Л value increased significantly, we thus suggest that
genomic variations we observed among different groups
of isolates are unlikely caused completely by phylogen-
etic lineages, but rather associated with diverse pheno-
types of the isolates. Secondly, this study was limited by
the relatively small number of isolates included in the
analysis. It is likely that a larger sample with diverse line-
ages and countries of origin would probably reveal more
information on genomic variations and evolution of
drug-resistant M. tuberculosis strains.
Conclusions
In this study, by performing whole genome sequencing
study, we show that though clinical M. tuberculosis iso-
lates have a certain degree of similarity in their genetic
make-up, they exhibit distinct variations in terms of the
distribution of SNP, Indels, CRISPR-cas locus, as well
as the nucleotide diversity and selection intensity. No
generalizable differences were identified between drug-
susceptible and drug-resistant isolates on the genomic
scale. Our study provides evidence strengthening the no-
tion that the evolution of drug resistance among clinical
M. tuberculosis isolates is clearly a complex and diversi-
fied process. Several questions remain further in-depth
investigations, such as whether drug susceptibility is af-
fected by the deletion of specific genes and disabling of
specific metabolic pathways. In addition, further studies
using a larger sampling of M. tuberculosis isolates from
diverse lineages are warranted to better understand the
evolution of drug-resistant M. tuberculosis strains.
Methods
Selection of strains for genome sequencing and
comparative genomic analysis
Seven M. tuberculosis clinical strains used for whole
genome sequencing in this study were obtained from a
TB referral hospital in Beijing, China during the period
2009–2011 [3]. The epidemiologic and clinical data of
the patients were extracted from the subjects’ medical
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had different antibiotic susceptibility profiles (including
1 susceptible isolate, 1 MDR isolate, 3 pre-XDR isolates
and 2 XDR isolate). The median age of the 7 patients
were 39.02 (range: 21–72) years. All 7 patients were
HIV-negative adults. All 7 isolates have the Beijing
spoligotype (000000000003771) based on the virtual spo-
ligotyping analysis results. For comparative analysis,
genome sequences of two lab strains including H37Rv
(NC_000962) and H37Ra (NC_009525) as well as other
five previously sequenced clinical isolates including
KZN_1435 (NC_012943), F11 (NC_009565), CDC1551
(NC_002755), CCDC5079 (NC_017523), and CCDC51
80 (NC_017522) were downloaded from the NCBI
website (fttp://ftp.ncbi.nih.gov/genomes/Bacteria/). This
study was approved by the Ethics Committee of the
309 Hospital and the Institute of Microbiology, Chinese
Academy of Sciences, Beijing, China.
Cultures and drug susceptibility testing
Cultures and drug susceptibility testing (DST) were con-
ducted as described previously [19]. Briefly, sputum
specimens were collected, treated and cultured accord-
ing to the manufacturer’s instructions using the BAC-
TEC MGIT 960 system (Becton Dickinson Diagnostic
Systems, Sparks, MD, USA). Cultures positive for growth
were examined by microscopy for the presence of acid-
fast bacilli after Ziehl-Neelsen staining. Identification of
M. tuberculosis was performed using p-nitrobenzoic acid
and thiophene carboxylic acid hydrazine resistance tests
as well as PCR tests. M. tuberculosis isolates were
further confirmed by 16S rDNA sequencing. DST was
conducted using the indirect proportion method on
Middlebrook 7H10 agar containing 10% oleic acid-
albumin-dextrose-catalase (Difco) and 0.5% glycerol ac-
cording to the WHO guidelines. The concentrations of
the drugs used were as follows: isoniazid (0.2 ug/mL),
rifampicin (1 ug/mL), ethambutol (5 ug/mL), strepto-
mycin (2 ug/mL), pyrazinamide (100 ug/mL), ofloxacin
(2 ug/mL), levofloxacin (2 ug/mL), kanamycin (5 ug/mL),
capreomycin (10 ug/mL), amikacin (1 ug/mL), ethion-
amide (5 ug/mL), para-aminosalicylic acid (2 ug/mL).
Quality control was performed during susceptibility test-
ing using the reference strains provided by the National
institute for the control of pharmaceutical and biological
products (China). All drugs were obtained from Sigma Life
Science Company (USA).
Genotyping of M. tuberculosis isolates
In silico MIRU-VNTR genotyping of the M. tuberculosis
isolates was conducted. To predict the number of re-
peats at each locus of MIRUs, 24 VNTR sequences from
H37Rv genome were aligned to each assembled genome.
The Tandem Repeat Finder algorithm was also used topredict the MIRU-VNTR type of each strain [35]. The in
silico MIRU-VNTR results were confirmed by perform-
ing experiments following the 24 locus MIRU-VNTR
genotyping protocol described by Supply et al. [6]. Vir-
tual spoligotyping was performed by aligning (without
gaps) all the reads obtained for each strain against each
of the 43 spacer sequences (26-bp oligos) from the direct
repeats (DR) regions. The number of matching reads for
each spacer was counted, considering both forward and
reverse-complemented sequences, and accepting up to 1
nucleotide mismatch. Spacers with 0 matches were inter-
preted as missing. In addition, we also used SpolPred
[36], a well-established genotyping technique based on
the presence of unique DNA sequences in M. tubercu-
losis, to predict the spoligotype of each strain.
DNA preparation and whole genome sequencing
A single colony from 7H10 plate was transferred into
7H9 liquid medium supplemented with OADC and
Tween-80, cultured to 0.5 at OD600, harvested by centri-
fugation and resuspended in TE pH8.0 [0.01 M Tris–
HCl, 0.001 M EDTA (pH 8.0)]. Genomic DNA was
extracted with phenol/chloroform/isoamyl alcohol (25:
24: 1, v/v), precipitated with isopropanol, washed with
75% ethanol and finally resuspended in TE pH8.0. Gen-
ome sequencing was performed by BerryGenomics
(Beijing, China). We used a whole genome shotgun
sequencing strategy and Illumina Genome Analyser
sequencing technology. A 100 bp paired-end run was
performed with the seven M. tuberculosis strains in two
lanes. Genomic DNA was sheared by a nebulizer to gen-
erate DNA fragments for the Illumina Paried-End
Sequencing method. DNA libraries (15–30 ng/μl) were
constructed by ligating the specific oligonucleotides
(Illumina adapters) designed for PE sequencing to both
ends of DNA fragments with the TA cloning method.
The ligated DNA was then size selected on a 2% agarose
gel. DNA fragments of about 500 bp were excised from
the gel. DNA was then recovered using a Qiagen gel ex-
traction kit and was PCR amplified to produce the final
DNA library. Five picomoles of DNA from each strain
were loaded onto two lanes of the sequencing chip, and
the clusters were generated on the cluster generation
station of the GAIIx using the Illumina cluster gener-
ation kit. Bacteriophage ×174 DNA was used as a con-
trol. In the case of paired-end reads, distinct adaptors
from Illumina were ligated to each end with PCR
primers that allowed reading of each end as separate
runs. The sequencing reaction was run for 100 cycles
(tagging, imaging, and cleavage of one terminal base at a
time), and four images of each tile on the chip were
taken in different wavelengths for exciting each base-
specific fluorophore. For paired-end reads, data were
collected as two sets of matched 100-bp reads. Reads for
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custom Perl script (Additional file 7: Script 1). Image
analysis and base calling were done using the Illumina
GA Pipeline software.
Genome assembly and annotation
Short reads were assembled using SOAPdenovo (http://
soap.genomics.org.cn), a genome assembler developed
specifically for next-generation short-read sequences. As
the algorithm is sensitive to sequencing errors, low-
quality reads were filtered, and high-quality reads were
used for de novo assembly. Sequences were filtered
for low quality reads using the DynamicTrim and
LengthSort Perl scripts within SolexaQA. These scripts
trimmed each read to the longest contiguous read seg-
ment for which the quality score at each base was
greater than p = 0.05 (approximately equivalent to a
Phred score of 13), and then removed sequence reads
shorter than 25 bp respectively. Where one sequence of
a pair was removed, the remaining sequence was put
into a separate file and used as a singleton during de
novo assembly. The SOAP GapCloser was also used to
close gaps where possible after assembly.
The protein-coding genes were predicted using Glim-
mer 3.02 [37], while tRNAscan-SE [38] and RNAmmer
[39] were used to identify tRNA and rRNA, respectively.
The genome sequence was also uploaded into Rapid
Annotation using Subsystem Technology (RAST) [40]
to check the annotated sequences. The functions of
predicted protein-coding genes were then annotated
through comparisons with the databases of NCBI-NR,
COG, and KEGG.Nucleotide sequence accession numbers
Whole genome sequencing projects for 7 clinical M.
tuberculosis isolates Mtb562, Mtb194, Mtb293, Mtb526,
Mtb940, Mtb984, and Mtb43 have been deposited
in GenBank under accession numbers AUTG00000000,
AUNH00000000, AUPX00000000, AUTF00000000, AU
TX00000000, AUTY00000000, and AUPO00000000,
respectively.
SNP detection and analysis
For the sequenced genomes, SOAPsnp (http://soap.gen-
omics.org.cn/soapsnp.html) was used to score SNPs
from aligned reads [41]. The short reads were aligned
onto the H37Rv genome reference using the SOAP2
program [18]. To obtain reliable alignment hits, at most
two mismatches were allowed between the read and the
reference. The alignments with the least number of dif-
ferences were defined as “best hits.” If there was only
one single best hit for a read, then the read was taken as
uniquely placed; a read with multiple equal best hits wastaken as repeatedly placed. For paired-end reads, two
reads belonging to a pair were aligned together with
both in the correct orientation and with a proper span
size on the reference. The 100-bp reads that were gener-
ated for each strain were mapped against H37Rv as a
reference sequence via ungapped alignments allowing up
to two mismatches. For reads that mapped to multiple
locations, one was chosen at random. For paired-end
data, mapping locations of each read were restricted to
sites within 300 bp of mapping locations of its partner.
SOAPsnp results were filtered as follows: 1) The read
coverage of the SNP site was more than five; 2) The Illu-
mina quality score of either allele was more than 30; 3)
The count of all mapped best base is more than two
times the count of all mapped second best base. In
addition, BWA 0.6.2 [42] and SAMtools 0.1.18 [43] were
used to confirm our results. The Illumina reads were
first aligned by BWA with default parameters for each
sample. The aligned results were piped to SAMtools for
conversion of BWA output format to BAM format and
to perform SNP analysis. For the other genomes, all spe-
cific SNPs for each strain were manually inspected by
taking into account if SNPs were detected by the two
aligners including MAUVE [44] and MUMmer 3.2 [45].
From all SNPs identified in the sequenced genome se-
quences, the density of SNPs was calculated throughout
the M. tuberculosis H37Rv genome using a sliding-
window size of 5 kb (step of the sliding window = 5 kb).
This analysis led to the construction of a SNP clustering
map using Circos [46].
Insertion and deletion (Indel) analysis
Three different methods were used to detect Indels:
1) Multiple alignment of genomic sequences was per-
formed by using Mauve multiple alignment software and
the progressive alignment option. The output file pro-
duced by Mauve was parsed by using a custom Perl
script to retrieve multiple aligned sequences for Indel
loci (Additional file 8: Script 2); 2) For each genome-
wide Ilumina sequence dataset, the sequence reads were
aligned against the reference genome sequence using
BWA 0.6.2 [42]. Then SAMTOOLS 0.1.18 [43], which is
based on a Bayesian model for Indel calling, was used to
perform the analysis using the default Indel detection
parameters, with a small increase in the coverage thresh-
old (−D 200); 3) Indel from paired-end mapping data
were identified and visualized with inGAP-SV [47],
which uses read depth and read pair data to detect and
visualize large and complex sequence variation.
CRISPR locus identification
For published genome sequences, CRISPR loci were re-
trieved from the CRISPRdb database [48]. Alternatively,
the detection of CRISPR loci in our 7 draft genome
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BLAST was used for similarity searches between CRISPR
spacer sequences and existing sequences in the GenBank
database limited to Bacteria (taxid: 2) or Viruses (taxid:
10239) entries. Only matches showing 100% identity over
the complete CRISPR spacer sequences were retained, and
matches to sequences found within CRISPR loci were
ignored.Identification of gene mutations associated with drug
resistance
Mutations in M. tuberculosis antibiotic resistance-associated
genes and inter-genic regions were downloaded from the
TB Drug Resistance Mutation Database (TBDReaMDB)
[49], a comprehensive database providing all reported muta-
tions associated with TB drug resistance through a publicly
accessible web site: http://www.tbdreamdb.com, to provide
information for comparison analysis of drug resistance-
associated mutation profiles for the 7 sequencedM. tubercu-
losis isolates. To confirm the association between specific
gene mutations and drug resistance, we amplified the puta-
tive drug resistance-associated genes with mutations from
the genomic DNA of clinical M. tuberculosis isolates by
PCR, and cloned them into the plasmid pMV261, a myco-
bacterial replicating vector, then electroporated the recom-
binant vectors into the drug-susceptible reference H37Rv
strain for drug susceptibility testing. All the experiments
were repeated at least 3 times.Genetic diversity and selection intensity analysis
The program DnaSP software version 5.10 was used to
investigate the genetic diversity of the whole genome se-
quences of the M. tuberculosis isolates [50]. The genetic
diversity were measured by haplotype (H), diversity of
haplotype (Hd), nucleotide diversity (p), and the average
number of nucleotide differences (K). The sequences of
the coding regions from each isolate were concatenated
and the resulting sequences were used to determine the
number of non-synonymous (dN) and synonymous (dS)
substitutions per site. To test the selection intensity, the
ratios of dN/dS were calculated for each pairwise com-
parison, and two-sided Z-test was used to determine the
level of significance.Phylogenetic analysis
The neighbor-joining (NJ) and maximum-likelihood (ML)
phylogenetic trees were constructed in MEGA5 [51] based
on SNPs from whole genome sequences. The reliability of
each node was estimated from 1000 random bootstrap
resamplings of the data. The phylogenetic data have been
deposited in TreeBase under the accession number 15638
(http://purl.org/phylo/treebase/phylows/study/TB2:S15638).Additional files
Additional file 1: Table S1. Sequencing statistics of M. tuberculosis isolates.
Additional file 2: Table S2. Regions with significantly high SNP density.
Additional file 3: Figure S1. Distribution of SNPs according to the
Clusters of Orthologous Groups (COG) classification. (U) Intracellular trafficking
and secretion; (V) Defense mechanisms; (D) Cell cycle control, mitosis, and
meiosis; (F) Nucleotide transport and metabolism; (O) Post-translational
modification, protein turnover, chaperones; [O] Posttranslational modification,
protein turnover, chaperones; [J] Translation, ribosomal structure and biogen-
esis; (H) Coenzyme transport and metabolism; [M] Cell wall/membrane/enve-
lope biogenesis; [S] Function unknown; [K] Transcription; (P) Inorganic ion
transport and metabolism; (T) Signal transduction mechanisms; (G) Carbohy-
drate transport and metabolism; (N) Cell motility; (C) Energy production and
conversion; (L) Replication, recombination, and repair; [E] Amino acid trans-
port and metabolism; (I) Lipid transport and metabolism; (R) General function;.
(Q) Secondary metabolites biosynthesis, transport, and catabolism. (*) Class
with significant over-representation and less-representation of SNPs (p < 0.01).
Additional file 4: Figure S2. Overview of the CRISPR loci in M. tuberculosis
strains. Spacers are shown as diamonds and repeats as rectangles. In each
CRISPR, spacers with identical sequence in the studied genomes are shown in
the same color.
Additional file 5: Table S3. Known or putative drug efflux pumps with
non-synonymous SNPs in MDR, pre-XDR and XDR M. tuberculosis isolates
but not in H37Rv strain.
Additional file 6: Table S4. DNA diversity and selection intensity
analysis for the whole genome sequences of M. tuberculosis isolates.
Additional file 7: Script 1. The custom Perl script used to separate
each of the indexed samples from raw reads.
Additional file 8: Script 2. The custom Perl script used to retrieve Indel
loci from output file (.xmfa) produced by Mauve.
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